Found: 3
Select item for more details and to access through your institution.
Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials.
- Published in:
- Science Translational Medicine, 2019, v. 11, n. 509, p. 1, doi. 10.1126/scitranslmed.aaw8412
- By:
- Publication type:
- Article
CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials.
- Published in:
- eLife, 2017, p. 1, doi. 10.7554/eLife.24179
- By:
- Publication type:
- Article
FABP1 controls hepatic transport and biotransformation of Δ<sup>9</sup>-THC.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1038/s41598-019-44108-3
- By:
- Publication type:
- Article